NO964859L - Fremgangsmåte for fremstilling av vannfrie og hydratformer av antihistaminiske piperidinderivater, polymorfer og pseudomorfer derav - Google Patents

Fremgangsmåte for fremstilling av vannfrie og hydratformer av antihistaminiske piperidinderivater, polymorfer og pseudomorfer derav

Info

Publication number
NO964859L
NO964859L NO964859A NO964859A NO964859L NO 964859 L NO964859 L NO 964859L NO 964859 A NO964859 A NO 964859A NO 964859 A NO964859 A NO 964859A NO 964859 L NO964859 L NO 964859L
Authority
NO
Norway
Prior art keywords
pseudomorphs
polymorphs
anhydrous
preparation
piperidine derivatives
Prior art date
Application number
NO964859A
Other languages
English (en)
Other versions
NO315319B1 (no
NO964859D0 (no
Inventor
Daniel Randolph Henton
Frederick Joseph Mccarty
Susan Irene Tripp
Jill Elizabeth Dewitt
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO964859(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of NO964859L publication Critical patent/NO964859L/no
Publication of NO964859D0 publication Critical patent/NO964859D0/no
Publication of NO315319B1 publication Critical patent/NO315319B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)
NO19964859A 1994-05-18 1996-11-15 Fremgangsmate for fremstilling av vannfrie former og hydratformer av antihistaminiske piperidinderivater, polymorfer og pseudomorfer derav NO315319B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11
PCT/US1995/004942 WO1995031437A1 (en) 1994-05-18 1995-04-28 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof

Publications (3)

Publication Number Publication Date
NO964859L true NO964859L (no) 1996-11-15
NO964859D0 NO964859D0 (no) 1996-11-15
NO315319B1 NO315319B1 (no) 2003-08-18

Family

ID=26937420

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964859A NO315319B1 (no) 1994-05-18 1996-11-15 Fremgangsmate for fremstilling av vannfrie former og hydratformer av antihistaminiske piperidinderivater, polymorfer og pseudomorfer derav

Country Status (17)

Country Link
US (12) US20010014741A1 (no)
EP (3) EP1178041A1 (no)
JP (7) JPH10500134A (no)
CN (3) CN1623985A (no)
AT (1) ATE220667T1 (no)
AU (1) AU693892B2 (no)
CA (3) CA2449419C (no)
DE (1) DE69527429T2 (no)
DK (1) DK0766668T3 (no)
ES (1) ES2176329T3 (no)
FI (1) FI964565A7 (no)
HU (1) HU227676B1 (no)
IL (3) IL113747A (no)
MX (1) MX9605613A (no)
NO (1) NO315319B1 (no)
PT (1) PT766668E (no)
WO (1) WO1995031437A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
CA2449419C (en) * 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0812195B1 (en) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
IN191492B (no) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
CZ20033019A3 (cs) * 2001-04-09 2004-07-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy chloridu fexofenadinu
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
CA2450858C (en) * 2001-06-18 2009-04-07 Dr. Reddy's Laboratories Limited Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-.alpha.,.alpha.-dimethylbenzene acetic acid and its hydrochloride
DE60225694T2 (de) * 2001-07-31 2008-06-26 Texcontor Etablissement Neues polymorph von fexo-fenadin
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
EP1474392A1 (en) * 2002-06-10 2004-11-10 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
CA2530193A1 (en) * 2003-07-03 2005-01-20 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
KR20070007196A (ko) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (en) * 2004-06-15 2006-02-08 Dipharma S.p.A. A process for the preparation of keto compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
KR20090037930A (ko) * 2006-07-11 2009-04-16 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 조절 방출 제형
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
EP2105134A1 (en) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stable amorphous fexofenadine hydrochloride
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN102595879B (zh) 2009-11-06 2014-08-06 巴斯夫欧洲公司 4-羟基苯甲酸和选定农药的结晶配合物
IT1400965B1 (it) 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
ES2403130B1 (es) 2010-06-15 2014-09-29 Chemelectiva S.R.L. Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
US3965257A (en) 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
BE794598A (fr) 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (no) 1991-04-08 1993-01-11 Green Cross Corp
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
HU226561B1 (en) 1992-04-10 2009-04-28 Merrell Dow Pharma Process for preparation 4-diphenylmethyl piperidine derivatives and the novel intermediates thereof
WO1993023047A1 (en) 1992-05-11 1993-11-25 Merrell Dow Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
FI950467A7 (fi) 1992-08-03 1995-03-31 Sepracor Inc Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit aller gisten sairauksien hoitamiseksi
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
HU226559B1 (en) 1993-06-24 2009-03-30 Amr Technology Process for the production of piperidine derivatives
CA2254506C (en) 1993-06-24 2000-11-28 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
EP1953142A1 (en) 1993-06-25 2008-08-06 Aventis Inc. Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives
CA2449419C (en) 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5576610A (en) 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
IL134769A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
EP0812195B1 (en) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
NZ501248A (en) 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
CZ20033019A3 (cs) * 2001-04-09 2004-07-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy chloridu fexofenadinu
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Also Published As

Publication number Publication date
CA2585705A1 (en) 1995-11-23
CN1148849A (zh) 1997-04-30
NO315319B1 (no) 2003-08-18
AU693892B2 (en) 1998-07-09
FI964565A0 (fi) 1996-11-14
US20040014976A1 (en) 2004-01-22
US20080167471A1 (en) 2008-07-10
IL134917A0 (en) 2001-05-20
CA2449419A1 (en) 1995-11-23
JP4503909B2 (ja) 2010-07-14
JP2002308850A (ja) 2002-10-23
PT766668E (pt) 2002-11-29
JP2002316978A (ja) 2002-10-31
MX9605613A (es) 1998-05-31
IL113747A (en) 2001-05-20
US7135571B2 (en) 2006-11-14
FI964565L (fi) 1996-11-14
HK1137742A1 (en) 2010-08-06
CN1907967B (zh) 2012-07-04
HU9603167D0 (en) 1997-01-28
HU227676B1 (en) 2011-11-28
DK0766668T3 (da) 2002-10-28
NO964859D0 (no) 1996-11-15
ATE220667T1 (de) 2002-08-15
JP2010120969A (ja) 2010-06-03
IL134917A (en) 2001-07-24
DE69527429D1 (de) 2002-08-22
EP1178041A1 (en) 2002-02-06
JP4503908B2 (ja) 2010-07-14
US7666881B2 (en) 2010-02-23
US20010025106A1 (en) 2001-09-27
US20070021462A1 (en) 2007-01-25
EP0766668A1 (en) 1997-04-09
US20030045721A1 (en) 2003-03-06
AU2426595A (en) 1995-12-05
CN1907967A (zh) 2007-02-07
US20010014741A1 (en) 2001-08-16
US20070021461A1 (en) 2007-01-25
JP2002255935A (ja) 2002-09-11
JP4503907B2 (ja) 2010-07-14
US20020193601A1 (en) 2002-12-19
ES2176329T3 (es) 2002-12-01
CA2585705C (en) 2012-04-17
CA2189007C (en) 2004-03-02
US20020193603A1 (en) 2002-12-19
CA2449419C (en) 2011-09-06
HUT76134A (en) 1997-06-30
FI964565A7 (fi) 1996-11-14
CA2189007A1 (en) 1995-11-23
US20020193600A1 (en) 2002-12-19
DE69527429T2 (de) 2003-03-20
US20010012896A1 (en) 2001-08-09
US7662835B2 (en) 2010-02-16
EP0766668B1 (en) 2002-07-17
IL113747A0 (en) 1995-08-31
HK1098467A1 (en) 2007-07-20
CN1623985A (zh) 2005-06-08
JPH10500134A (ja) 1998-01-06
US20080167469A1 (en) 2008-07-10
US7138524B2 (en) 2006-11-21
EP2354125A1 (en) 2011-08-10
JP2002308849A (ja) 2002-10-23
JP2002255936A (ja) 2002-09-11
WO1995031437A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
NO964859D0 (no) Fremgangsmåte for fremstilling av vannfrie og hydratformer av antihistaminiske piperidinderivater, polymorfer og pseudomorfer derav
DE68916699D1 (de) Benzopyridopiperidin, -piperidyliden und -piperazin-Verbindungen, Zusammensetzungen, Methoden zur Herstellung und Verwendung.
DK0646115T3 (da) Heterocykliske/cykliske aminderivater
NO874350D0 (no) Fremgangsmaate for fremstilling av antibakterielle forbindelser.
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
DE69401817D1 (de) Verbesserungen zum herstellen von glasartigem silika
FI890245A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1,4-disubstituoitujen piperidinyylijohdannaisten valmistamiseksi
DK6384D0 (da) Disubstituerede prolinderivater, fremgangsmade til fremstilling deraf og deres anvendelse
PT88656A (pt) Process for preparing 4-aminopyridine derivatives
NO904135L (no) Fremgangsmaate for fremstilling av nye substituerte alkylpiperidiner og deres anvendelse som inhibitorer av kolesterolsyntese.
DK0483633T3 (da) 8-Azabicyclo 3,2,1 octylalkylthiazoliddinoner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler.

Legal Events

Date Code Title Description
MK1K Patent expired